Over the past decades, the amount of people referred for allogeneic hematopoietic mobile transplantation has dropped noticeably,133 although the procedure should be suggested to young/match patients in whom BCR/BCL2 inhibitor treatment fails, specially in These with TP53This methylation profile is previously obtained for the MBL stage3 and remains